Incidence and economic burden of suspected adverse events and adverse event monitoring during AF therapy

Author： Kim M.H.   Lin J.   Hussein M.   Battleman D.  

Publisher： Informa Healthcare

ISSN： 1473-4877

Source： Current Medical Research and Opinion, Vol.25, Iss.12, 2009-12, pp. : 3037-3047

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

The burden of adverse drug events

By  

BRITISH JOURNAL OF CLINICAL PHARMACOLOGY (ELECTRONIC), Vol. 80, Iss. 4, 2015-10 ,pp. : 785-787

John Wiley & Sons Inc

Access to resources Recommend Favorite

An Evaluation of Risk Factors for Major Adverse Cardiovascular Events During Tocilizumab Therapy

By  

ARTHRITIS & RHEUMATOLOGY, Vol. 67, Iss. 2, 2015-02 ,pp. : 372-380

John Wiley & Sons Inc

Access to resources Recommend Favorite

Economic burden of selected adverse events in patients aged ≥65 years with metastatic renal cell carcinoma

By Hagiwara May   Hackshaw Michelle D.   Oster Gerry  

Journal of Medical Economics, Vol. 16, Iss. 11, 2013-11 ,pp. : 1300-1306

Informa Healthcare

Access to resources Recommend Favorite

Adverse event monitoring in oncology clinical trials

By Russell Jeffery S   Colevas A Dimitrios  

Clinical Investigation, Vol. 3, Iss. 12, 2013-12 ,pp. : 1157-1165

Future Science

Access to resources Recommend Favorite

Incidence and types of adverse events during mass vaccination campaign with the meningococcal a conjugate vaccine (MENAFRIVAC™) in Cameroon

By  

PHARMACOEPIDEMIOLOGY AND DRUG SAFETY, Vol. 25, Iss. 10, 2016-10 ,pp. : 1170-1178

John Wiley & Sons Inc

Access to resources Recommend Favorite